Brought to you by 
Adimab completes $4mm Series E financing
08 Apr 2011
Executive Summary
OrbiMed Advisors was the lead investor on antibody platform developer Adimab LLC’s $4mm Series E financing. According to the Form D filing, nine other undisclosed backers participated (a secondary industry source reports that all existing shareholders joined, including Google Ventures, Borealis Ventures, Polaris Venture Partners, and SV Life Sciences). The company had a pre-money valuation of $520mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Adimab completes $4mm Series E financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice